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Abstract
Background: Risk of screen-detected breast cancer mostly reflects inherent risk, while risk of interval cancer reflects
inherent risk and risk of masking (risk of the tumor not being detected due to increased dense tissue). Therefore
the predictors of whether a breast cancer is interval or screen-detected include those that predict masking. Our aim
was to investigate the associations between mammographic measures and (1) inherent risk, and (2) masking.
Methods: We conducted a case-control study nested within the Melbourne collaborative cohort study of 244
screen-detected cases (192 small tumors (<2 cm)) matched to 700 controls and 148 interval cases (76 small tumors)
matched to 446 controls. Dense area (DA), percent dense area (PDA), and non-dense area (NDA) were measured
using the Cumulus software. Conditional and unconditional logistic regression were applied as appropriate to estimate
the odds per adjusted standard deviation (OPERA) adjusted for age and body mass index (BMI), allowing for the
association with BMI to be a function of age at diagnosis. Tests of fit were performed using the Bayesian information
criterion (BIC) and the area under the receiver operating characteristic curve.
Results: For screen-detected cancer, the association with BMI had a marginally significant dependence on age at
diagnosis, and after adjustment both DA and PDA were associated with risk (OPERA approximately 1.2) and gave a
similar fit. NDA was not associated with risk. For interval cancer, the BMI risk association was not dependent on age at
diagnosis and the best fitting model was PDA alone (OPERA = 2.24, 95 % confidence interval 1.75, 2.86). Prediction of
interval versus screen-detected cancer was best achieved by PDA alone (OPERA = 1.76, 95 % confidence interval
1.39, 2.22) with no association with BMI. When the analysis was restricted to small tumors to reduce the influence
of tumor growth, we obtained similar results.
Conclusions: Inherent breast cancer risk is predicted by BMI and DA or PDA, but not NDA. Masking is predicted
by PDA, and not by BMI. Understanding risk and masking could help tailor mammographic screening.
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Background
The regions of the breast that appear white or bright on a
mammogram are referred to as being mammographically
dense, and are usually measured in terms of their absolute
area on the mammogram (dense area, DA), or in terms of
the percentage of the total area on the mammogram cov-
ered by dense area (percent dense area, PDA). These mam-
mographic density (MD) measures, after adjustment for
age and body mass index (BMI) due to negative confound-
ing, are positively associated with risk of developing breast
cancer [1–5]. There are also suggestions of a positive asso-
ciation between MD and risk of masking of breast tumors
[1, 2, 5] and rate of tumor growth [6]. Masking of a breast
tumor is defined as a tumor being hidden on a mammo-
gram and not being detected due to the similar appearances
of both mammographically dense regions and the tumor,
thus, decreasing the sensitivity of mammography.
The mammographic regions that appear non-white are
referred to as non-dense area (NDA), and their negative
association with overall risk of breast cancer - without
differentiation between risk of developing breast cancer,
masking and growth rate - is controversial [3, 7]. NDA is
presumed to represent mostly fat tissue; however, even after
adjusting for BMI and DA, with which it is negatively cor-
related, it has been found to be negatively associated with
breast cancer risk [7]. The interpretation of this finding is
not obvious, especially given the well-documented involve-
ment of adiposity in the postmenopausal period in path-
ways triggering aromatase expression and increasing
postmenopausal risk [8]. Also, DA and NDA are typically
negatively correlated, so the aforementioned associations in
different directions could just be reflecting “both sides of
the same coin”, as we postulated in our previous paper [7].
Therefore, the concurrent associations between devel-
oping and masking of a breast tumor and the different
mammography measures, DA, PDA and NDA, is unclear.
The role of different rates of tumor growth also poses
additional challenges.
The risk of a woman being diagnosed with breast can-
cer, given age, BMI and MD measures, is the combination
of: (1) her inherent risk of developing breast cancer; (2)
her risk of having any existing tumor masked; and (3) the
growth rate of her tumor should she develop one. We as-
sumed the risk of screen-detected breast cancer is mostly
influenced by inherent risk, while risk of interval breast
cancer is due to a combination of inherent risk and risk of
masking. Therefore, given a woman is diagnosed with
breast cancer, the factors that differentiate her having a
screen-detected versus an interval cancer will mostly be
those that influence risk of masking. Restricting the ana-
lysis to small tumors should lessen the influence on the
latter due to the growth rate of tumors.
We have previously reported on the associations be-
tween DA, PDA and NDA, and breast cancer risk, while
allowing for the associations with BMI to vary with age at
diagnosis, using a case-control study nested within the
Melbourne collaborative cohort study (MCCS) [7]. Here
we have used the same study to investigate the risks of de-
veloping breast tumors and the risk of masking, by analyz-
ing cases by tumor detection mode and tumor size.
Tumor detection mode was categorized as screen-
detected (defined as being detected at a scheduled screen-
ing) or interval (defined as being detected after a negative
screening and before the next scheduled screening). We
estimated inherent risk by comparing screen-detected
cases with their matched controls, and risk of masking by
comparing interval cases with screen-detected cases. In
order to minimize the effect of tumor growth, we con-
ducted analyses stratified by tumor size.
Methods
The MCCS is a prospective cohort study of 41,514
people (24,469 women) aged between 27 and 76 years at
study entry (99.3 % of whom were aged 40–69 years).
Participants were recruited between 1990 and 1994 from
the Melbourne metropolitan area. In 2009, through a
record linkage between the MCCS and BreastScreen
Victoria, a population-based screening program, we
identified 20,444 (84 %) women in the MCCS who had
attended BreastScreen Victoria at least once and were
eligible for this study.
We then designed a nested case-control study using
incidence density sampling. Cases were women with a
first diagnosis of invasive adenocarcinoma of the breast
(International Classification of Diseases for Oncology
codes C50.0–C50.9). Each case was matched randomly
to four controls by year of birth, year of entry into the
MCCS and country of origin (Australia/New Zealand/
United Kingdom/others, Italy, or Greece). We selected
the mammogram closest to baseline and of the contra-
lateral breast with respect to the laterality of the tumor
in the matching case. Only craniocaudal-projection im-
ages were used in this study. Further details about the
nested case-control study based on the MCCS have been
published elsewhere [7, 9].
Screen-detected cases were identified at BreastScreen
Victoria and interval cases were defined as those diag-
nosed within 2 years of a negative screening at BreastSc-
reen Victoria (the recommendation for mammographic
screening for breast cancer in Australia is biennial). The
cases were further categorized by tumor size as small
tumors (<2 cm) and large tumors (≥2 cm), given that
breast cancer stage is based on cutoffs of 2 cm or 5 cm.
For this study, we excluded 61 screen-detected cases
detected at their first screening and 52 cases diagnosed
more than 2 years after a negative screen.
There were 244 screen-detected cases (192 (79 %) with
small tumors; 49 (20 %) with large tumors) matched to
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700 controls and 148 interval cases (76 (51 %) with small
tumors; 65 (44 %) with large tumors) matched to 446
controls.
Statistical analyses
We estimated associations between the mammographic
measures and risk according to the following different
models: (1) BMI only; (2) BMI and a function of DA and
NDA, with either as a linear combination or PDA; (3)
BMI and only DA; and (4) all of the above models with
mammographic measures without including BMI. The
association between BMI and risk was fitted as a func-
tion of age at diagnosis of the case as a reference age,
see below. BMI was measured at baseline attendance.
To compare the strength of risk factors, in the sense
of how well they discriminate cases from controls, we
presented model estimates in terms of odds per adjusted
standard deviation (OPERA) [10], which is the risk asso-
ciated with increase in the risk factor X (holding all
other factors taken into account either in the design or
model) on the scale of 1 (standard deviation) SD of X
after adjusting the mean of X for all the other variables
taken into account either by design or adjustment. This
allows statistically independent comparisons of the
disease-discrimination power of each of the different risk
factors, as recently demonstrated [11, 12].
The Box-Cox method was applied in the controls to
identify the appropriate transformations of the mammo-
graphic measures to achieve approximate normal distri-
butions; DA and PDA were transformed to (DA0.2-1)/0.2
and (PDA0.2-1)/0.2, respectively, while NDA was trans-
formed to (NDA0.5-1)/0.5. Each transformed mammo-
graphic measure was adjusted for age at mammogram,
BMI (standardized according to the controls) and all the
matching variables by fitting linear regression, and the
standardized residuals were obtained.
To estimate the OPERA associated with each mammo-
graphic measure, conditional logistic regression was fitted
adjusting for age at mammogram with the standardized
residuals corresponding to each mammographic measure,
separately, for screen-detected and interval cancers.
Letting r be the correlation between the standardized
residuals of DA and NDA (denoted as DA’ and NDA’,
respectively), when fitting together DA’ and NDA’ in the
model, to obtain the OPERA of DA’ we multiplied log(O-
PERA) of DA’ with [(1-r2)]0.5, which is the standard
deviation of DA’ after adjusting for NDA’. Similarly, we
obtained the OPERA for NDA’.
BMI measured at cohort entry was standardized ac-
cording to the mean and SD of the controls. To allow
the association between BMI and risk to be dependent
on age, an interaction term between the standardized
BMI and reference age (age at diagnosis for the case and
for its matched controls) was fitted in the models. The
likelihood ratio test was applied to test the significance
of the interaction between BMI and reference age.
To estimate the OPERA for having interval versus
screen-detected breast cancer we fitted unconditional
logistic regression to data from cases only. BMI and all
three mammographic measures were included in the same
format as mentioned above and the models were adjusted
for age at mammogram. For these analyses we presented
only the estimates when fitting BMI as a constant because
we found no evidence that the association between BMI
and mode of detection depended on age at diagnosis.
Relative goodness of fit was assessed by the Bayesian in-
formation criterion (BIC), and by the area under the re-
ceiver operating characteristic curve (AUC). We also
tested for differences between AUCs using De Long’s test
[13]. To compare the estimates corresponding to risk of
small tumors and large tumors we applied the Student’s
two-sided t test, assuming independence of normally dis-
tributed log(OPERA) estimates with a standard deviation
consistent with the width of the confidence interval (CI).
There is a slight overlap in the datasets used to estimate
risk of small and large tumors due to the design properties
of the nested case-control study and therefore, there is a
possibility of overestimation of a significant difference.
We conducted sensitivity analyses using unconditional
logistic regression in which we made further adjustments
for the following potential confounders that were assessed
at cohort entry: BMI at age 18–21 years; age at menarche;
parity and lactation; menopausal status; use of hormone
replacement therapy (HRT); use of oral contraceptives
(OC); alcohol consumption and energy intake; and the
matching variables (country of birth, year of birth, year of
cohort entry and reference age). These analyses were also
repeated using only those women who had undergone
mammography within 5 years of cohort entry.
We also conducted the following sensitivity analyses:
(1) excluding cases diagnosed between 1 and 2 years
after negative screening, and their matched controls; (2)
excluding ever-users of HRT; and (3) excluding cases di-
agnosed within 2 years of the mammogram, and their
matching controls. Statistical analyses were performed
using Stata 12.1 (Stata Corporation, College Station,
TX). A two-sided P value <0.05 was considered to be
nominally statistically significant.
Results
Table 1 presents characteristics of the study sample, and
shows that there were no differences between cases and
controls in age at which mammography was performed,
either by detection mode or by detection mode and
tumor size. Screen-detected cases were on average older
than interval cases when diagnosed (65 years vs 62 years,
P < 0.001), older at baseline when covariates were mea-
sured (56 years vs 54 years, P = 0.01), and older when
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Table 1 Characteristics of study participants
Screen-detected cases Interval cases
Cases (n = 244) Controls (n = 700) P Cases (n = 148) Controls (n = 446) P Pa
Age at baseline, years 56 (8) 56 (8) 0.72 54 (8) 54 (8) 0.72 0.01
Age at mammogram, years 59 (7) 59 (7) 0.82 57 (7) 57 (7) 0.79 <0.01
Age at diagnosis, years 65 (7) 62 (7) <0.001
Time between age at mammogram and
reference age, years
6 (3) 6 (3) 0.58 5 (3) 5 (4) 0.93 0.12
Total energy intake, MJ/day 8.4 (2.9) 8.6 (3.5) 0.40 8.7 (3.2) 8.7 (3.1) 0.91 0.30
BMI, kg/m2
All women 27.5 (4.9) 26.7 (4.9) 0.04 26.7 (5.3) 26.5 (4.8) 0.68 0.11
Premenopausal 27.2 (5.7) 26.2 (5.0) 0.17 25.9 (4.9) 26.1 (4.6) 0.72 0.15
Postmenopausal 27.6 (4.6) 27.0 (4.9) 0.10 27.2 (5.5) 26.7 (5.0) 0.41 0.51
BMI at age 18–21 years, kg/m2 21.5 (2.9) 21.5 (2.9) 0.86 21.4 (2.5) 21.5 (2.8) 0.54 0.66
Breast
Total area, cm2 143.7 (60.9) 137.8 (57.6) 0.17 125.0 (56.9) 133.4 (60.3) 0.14 <0.01
Non-dense area, cm2 124.2 (62.1) 120.9 (58.8) 0.47 96.5 (55.6) 115.3 (60.6) <0.001 <0.0001
Dense area, cm2 19.6 (21.7) 16.8 (20.6) 0.08 28.5 (24.5) 18.1 (19.4) <0.0001 <0.001
Percent dense area 15.5 (15.7) 14.0 (15.3) 0.18 25.2 (17.9) 15.4 (14.7) <0.0001 <0.0001
Country of birth, n (%)
Anglo Saxon/other 204 (84) 583 (83) 0.99 123 (83) 371 (83) 0.99 0.70
Italy 25 (10) 74 (11) 13 (9) 40 (9)
Greece 15 (6) 43 (6) 12 (8) 35 (8)
Age at menarche, years n (%)
<12 47 (19) 125 (18) 0.92 31 (21) 75 (17) 0.69 0.74
12 52 (21) 145 (21) 25 (17) 86 (19)
13 55 (23) 169 (24) 36 (24) 111 (25)
14+ 88 (36) 261 (37) 56 (38) 174 (39)
Parity and lactation, n (%),
Nulliparous 38 (16) 84 (12) 0.03 25 (17) 62 (14) 0.63 0.22
Parous, never lactated 10 (4) 61 (9) 12 (8) 34 (8)
Parous, lactated 190 (78) 542 (77) 108 (73) 343 (77)
Menopausal status n (%)
Premenopausal 69 (28) 195 (28) 0.88 59 (40) 170 (38) 0.72 0.02
Postmenopausal 174 (71) 504 (72) 89 (60) 275 (62)
Hormone replacement therapy use, n (%)
Never 169 (69) 493 (70) 0.75 98 (66) 323 (72) 0.17 0.55
Ever 74 (30) 205 (29) 49 (33) 122 (27)
Oral contraceptive use, n (%)
Never 93 (38) 283 (40) 0.53 58 (39) 157 (35) 0.4 0.86
Ever 150 (61) 415 (59) 90 (61) 287 (64)
Alcohol consumption, n (%)
Lifetime abstainers 109 (45) 257 (37) 0.10 43 (29) 160 (36) 0.3 <0.01
Ex-drinkers 13 (5) 24 (3) 3 (2) 13 (3)
Low intake, 1–19 g/day 97 (40) 337 (48) 78 (53) 223 (50)
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the mammogram closest to study entry was performed
(59 years vs 57 years, P < 0.01).
Screen-detected cases had on average similar DA and
PDA compared to controls (P = 0.08 and 0.18, respect-
ively). Interval cases had on average greater DA and
PDA and lesser NDA compared to controls (P < 0.001).
Compared to screen-detected cases, interval cases had
on average greater DA and PDA and lesser total breast
area and NDA (P < 0.01). Among screen-detected
cases, those with small tumors had on average lesser DA
(P = 0.01) but not lesser PDA (P = 0.11) than those with
large tumors. Similarly, among interval cases, those with
small tumors had on average lesser DA (P < 0.01) but not
lesser PDA (P = 0.26) than those with large tumors.
Screen-detected cases had a greater BMI than the controls
(P = 0.04), whereas there was no significant difference
in BMI between interval cases and controls (P = 0.68).
Of the women who answered the question about history
of family breast cancer, the proportion who reported any
family history of breast cancer was higher among those
with interval and screen-detected cancers (20 % and 16 %,
respectively) than it was among their respective controls
(10 % and 11 %, respectively) (P < 0.001 and P = 0.08,
respectively), although the difference between screen-
detected cases and controls was marginally significant.
Among screen-detected cases there was a greater percent-
age of women who had no children compared to controls
(16 % vs 12 %, P =0.03).
In terms of tumor characteristics, interval cases were
diagnosed with more tumors with poorer prognosis than
screen-detected cases; estrogen receptor (ER)-negative
(ER-) (30 % vs 18 %, P < 0.01), progesterone receptor
(PR)-negative (PR-) (54 % vs 43 %, P = 0.02), poorly dif-
ferentiated tumors (41 % vs 27 %, P < 0.01), positive
nodal status (44 % vs 16 %, P < 0.001), and larger tumor
size, ≥2 cm (44 % vs 20 %, P < 0.001).
Table 2 shows that the association between BMI and risk
of screen-detected breast cancer was almost null at 50 years
Table 1 Characteristics of study participants (Continued)
Medium intake, 20–39 g/day 19 (8) 61 (9) 20 (14) 38 (9)
High intake, ≥40 g/day 6 (2) 21 (3) 4 (3) 12 (3)
Family history of breast cancerb, n (%)
No 185 (76) 548 (78) 0.08 101 (68) 341 (76) <0.001 0.18
Yes 38 (16) 77 (11) 30 (20) 43 (10)
ER, n (%)
Positive 188 (77.0) 94 (63.5) <0.01
Negative 45 (18.4) 45 (30.4)
PR, n (%)
Positive 126 (51.6) 57 (38.5) 0.02
Negative 106 (43.4) 80 (54.1)
HER2, n (%)
Positive 73 (29.9) 41 (27.7) 0.64
Negative 153 (62.7) 96 (64.9)
Grade n (%)
Well-differentiated 62 (25.4) 24 (16.2) <0.01
Moderately differentiated 104 (42.6) 52 (35.1)
Poorly differentiated 65 (26.6) 61 (41.2)
Nodal status, n (%)
Positive 39 (16.0) 65 (43.9) <0.001
Negative 190 (77.9) 71 (48.0)
Tumor size, n (%)
<1 cm 76 (31.1) 25 (16.9) <0.001
1–2 cm 116 (47.5) 51 (34.5)
≥2 cm 49 (20.1) 65 (43.9)
Results are presented as mean (SD) unless stated otherwise. P values are for Pearson’s χ2 test or Fisher’s exact test for categorical variables and Student’s two-
sided t test for continuous variables. aP values are for tests comparing screen-detected cases with interval cases. bFamily history of breast cancer is defined as
having any relative with breast cancer. BMI body mass index, SD standard deviation, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal
growth factor receptor-2
Krishnan et al. Breast Cancer Research  (2016) 18:63 Page 5 of 13
Table 2 Risk of breast cancer according to BMI and mammographic measures, by detection mode
OPERA (95 % CI)
BMI BMI + DA + NDA BMI + PDA BMI + DA DA + NDA PDA DA
Screen-detected cases BIC, AUC 653, 0.63 660, 0.65 653, 0.65 654, 0.65 654, 0.62 646, 0.63 647, 0.62
(244 cases/700 controls) BMI per 1 SD
At age 50 years 0.92 (0.66, 1.27) 0.93 (0.67, 1.30) 0.94 (0.68, 1.30) 0.94 (0.67, 1.30)
At age 70 years 1.29 (1.07, 1.56) 1.30 (1.07, 1.57) 1.29 (1.07, 1.56) 1.30 (1.07, 1.57)
P for interactiona 0.09 0.11 0.12 0.11
DA per adjusted 1 SD 1.19 (1.04, 1.38) 1.20 (1.04, 1.39) 1.19 (1.03, 1.37) 1.20 (1.04, 1.39)
PDA per adjusted 1 SD 1.22 (1.05, 1.41) 1.22 (1.05, 1.41)
NDA per adjusted 1 SD 0.95 (0.82, 1.11) 0.95 (0.82, 1.11)
Interval cases BIC, AUC 420, 0.60 376, 0.76 373, 0.75 388, 0.72 364, 0.75 361, 0.75 377, 0.72
(148 cases/446 controls) BMI per 1 SD
At age 50 years 0.92 (0.63, 1.35) 0.81 (0.54, 1.22) 0.80 (0.54, 1.20) 0.82 (0.54, 1.23)
At age 70 years 1.12 (0.84, 1.49) 1.12 (0.82, 1.52) 1.10 (0.81, 1.49) 1.09 (0.81, 1.46)
P for interactiona 0.49 0.29 0.29 0.33
DA per adjusted 1 SD 1.89 (1.51, 2.36) 1.90 (1.53, 2.37) 1.87 (1.49, 2.33) 1.88 (1.52, 2.34)
PDA per adjusted 1 SD 2.27 (1.77, 2.92) 2.24 (1.75, 2.86)
NDA per adjusted 1 SD 0.63 (0.50, 0.78) 0.63 (0.51, 0.78)
All of the estimates from conditional logistic regression were adjusted for age at mammogram and the variables included into the model. AUC area under the receiver operating characteristic curve, BIC Bayesian
information criterion, BMI body mass index, CI confidence interval, DA dense area, NDA non-dense area, OPERA odds per adjusted standard deviation, PDA percent dense area, SD standard deviation. aLikelihood ratio











and increased with age at diagnosis in all models by about
30 % from 50 to 70 years, but the interaction between BMI
and age was marginally significant (0.09 ≤ P ≤ 0.12). Both
DA and PDA were positively associated with the risk of
screen-detected breast cancer with a similar increase in
risk of about 20 % per adjusted SD in all models. Models
including either DA or PDA gave the best fit (BIC = 647
and BIC = 646, respectively). NDA was not associated with
risk of screen-detected cancer in any model.
Table 2 shows a different set of results for risk of inter-
val breast cancer. First, there was no evidence that the
association between BMI and risk depended on age at
diagnosis (P ≥ 0.29). The best fitting model under the
BIC involved PDA alone, with an increase in risk of
about 124 % (95 % CI 75 %, 186 %) per adjusted SD.
Table 3 shows that the association between BMI and risk
of small screen-detected breast cancers increased by 32 %
from 50 to 70 years although the association was only mar-
ginally dependent on age at diagnosis (0.10 ≤ P ≤ 0.12). The
positive association with DA and PDA remained but the
risk estimates were about 10 % per adjusted SD and mar-
ginally significant. In contrast, risk of large screen-detected
cancers was not associated with BMI, whether fitted as
dependent or independent of age at diagnosis (results not
shown). The association between risk and DA or PDA was
59 % and 66 % per adjusted SD, respectively. The differ-
ences in the association between risk and DA or PDA
according to size of tumor were nominally significant.
There was no association between NDA and risk of small
or large screen-detected breast cancer.
Table 3 also shows that risk of both small and large
interval breast cancers was best fit by including PDA.
Similar to the screen-detected cancers, for interval can-
cers, the results for small tumors were similar to those for
overall tumors and association between mammographic
density (MD) and risk was significantly stronger for large
tumors than for small tumors.
Table 4 shows that the risk of interval vs screen-
detected breast cancer was independent of BMI, and was
best predicted by PDA alone. Results were similar when
analysis was restricted to small tumors. Furthermore, the
risk gradient with PDA was greater as a predictor of
large tumors than it was as a predictor of small tumors,
but the difference was not significant.
The findings were similar when we adjusted for all the
confounders and further restricted the analysis to mam-
mograms performed within 5 years of cohort entry. No
substantial differences in estimates were observed from
the sensitivity analyses (Additional file 1: Tables S1 to S9).
Discussion
We found that the best-fitting risk models differed sub-
stantially between screen-detected and interval, or interval
vs screen-detected breast cancers. Given our contention
that the risk of screen-detected cancers mostly reflects in-
herent cancer risk, and the predictors of interval vs
screen-detected disease mostly reflect predictors of mask-
ing, we conclude that after adjusting for age and BMI,
both DA or PDA, but not NDA, were associated with in-
herent risk of breast cancer. In contrast, masking was best
predicted by PDA alone, and is not predicted by BMI.
We have interpreted our risk estimates for screen-
detected breast cancer to be broadly representative of
woman’s inherent risk of developing a detectable breast
tumor, given that the cases did not have a detectable
tumor on prior mammograms. This could be a reasonable
assumption based on a review [14], which found that
within interval cases, which consist of true interval cases,
false-negative cases (tumors not identified on mammog-
raphy due to reader error) and occult tumors (tumors not
identified on mammography due to high density), there
was a lesser percentage of the latter two cases; false-
negative cases (25–40 %) and occult tumors (8–12 %).
Our finding that the association between screen-detected
cancer and BMI depends marginally on age at diagnosis is
consistent with the epidemiological literature that has consist-
ently identified a different association between BMI and risk of
breast cancer for premenopausal and postmenopausal disease
[15]. BMI has a negative association with risk of premeno-
pausal disease, and a positive association with risk of postmen-
opausal disease. We also used the MCCS to model the
temporal aspects of the latter phenomenon with a similar re-
sult [16].
After adjusting for BMI as aforementioned, either DA
or PDA, but not NDA, were associated with screen-
detected disease. Note that after adjusting for age and
BMI, DA and PDA were highly correlated (Spearman’s
rank correlation = 0.87). Therefore, it is not surprising
that they were associated with similar risk gradients
once risk was expressed on the age-adjusted and BMI-
adjusted scale using OPERA [10]. The AUCs and BICs
were similar. There were similar results for DA and/or
PDA in previous and larger studies analyzing screen-
detected cases, but they had not adjusted for BMI [17, 18],
nor had they adjusted for BMI only as a constant [19].
Our finding that NDA was not associated with screen-
detected disease is important given the controversy about
the potential for NDA to be implicated in breast cancer
risk [20]. When analyzing risk of interval versus screen-
detected cancer, the role of NDA in predicting masking,
after adjusting for DA, was in a different direction for
these two negatively associated measures. This suggests
that we might have been correct when we considered DA
and NDA to be “two sides of the same coin” when dis-
cussing these issues previously [7].
Both DA and PDA gave a similar fit when analyzing risk
of screen-detected cancer and when further restricted to
small tumors. Recent findings from studies of single
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Table 3 Risk of breast cancer according to BMI and mammographic measures, by detection mode and tumor size
OPERA (95 % CI)
BMI BMI + DA + NDA BMI + PDA BMI + DA DA + NDA PDA DA
Screen-detected, small tumors BIC, AUC 516, 0.64 528, 0.65 521, 0.65 521, 0.65 521, 0.62 515, 0.62 515, 0.62
(192 cases/552 controls) BMI per 1 SD
At age 50 years 0.91 (0.64, 1.31) 0.92 (0.64, 1.33) 0.93 (0.65, 1.33) 0.93 (0.65, 1.33)
At age 70 years 1.32 (1.07, 1.62) 1.32 (1.08, 1.62) 1.32 (1.07, 1.62) 1.32 (1.07, 1.62)
P for interactiona 0.10 0.11 0.12 0.12
DA per adjusted 1 SD 1.09 (0.93, 1.28) 1.10 (0.93, 1.29) 1.08 (0.92, 1.28) 1.09 (0.93, 1.28)
PDA per adjusted 1 SD 1.12 (0.94, 1.32) 1.11 (0.94, 1.31)
NDA per adjusted 1 SD 0.96 (0.82, 1.13) 0.97 (0.82, 1.14)
Screen-detected, large tumors BIC, AUC 145, 0.60 147, 0.69 142, 0.69 142, 0.69 136, 0.69 132, 0.69 132, 0.69
(49 cases/141 controls) BMI per 1 SD
At age 50 years 0.78 (0.32, 1.92) 0.83 (0.32, 2.14) 0.83 (0.33, 2.10) 0.79 (0.30, 2.07)
At age 70 years 1.14 (0.71, 1.83) 1.09 (0.64, 1.84) 1.10 (0.65, 1.85) 1.11 (0.66, 1.87)
P for interactiona 0.49 0.65 0.63 0.56
DA per adjusted 1 SD 1.56 (1.12, 2.19) 1.58 (1.12, 2.22) 1.57 (1.12, 2.20) 1.59 (1.13, 2.24)
PDA per adjusted 1 SD 1.64 (1.13, 2.38) 1.66 (1.14, 2.40)
NDA per adjusted 1 SD 0.85 (0.58, 1.24) 0.84 (0.57, 1.22)
Interval cases, small tumors BIC, AUC 217, 0.62 208, 0.74 203, 0.74 211, 0.70 199, 0.73 194, 0.73 203, 0.69
(76 cases/224 controls) BMI per 1 SD
At age 50 years 0.76 (0.43, 1.32) 0.68 (0.37, 1.25) 0.68 (0.37, 1.24) 0.70 (0.38, 1.26)
At age 70 years 0.88 (0.54, 1.43) 0.96 (0.58, 1.57) 0.93 (0.57, 1.51) 0.89 (0.55, 1.46)
P for interactiona 0.73 0.46 0.49 0.58
DA per adjusted 1 SD 1.65 (1.22, 2.23) 1.64 (1.22, 2.21) 1.61 (1.20, 2.17) 1.60 (1.20, 2.15)
PDA per adjusted 1 SD 1.99 (1.43, 2.77) 1.94 (1.40, 2.68)
NDA per adjusted 1 SD 0.65 (0.48, 0.86) 0.65 (0.49, 0.86)
Interval cases, large tumors BIC, AUC 196, 0.59 163, 0.82 159, 0.82 167, 0.79 152, 0.82 148, 0.82 156, 0.79
(65 cases/204 controls) BMI per 1 SD
At age 50 years 1.23 (0.67, 2.23) 0.99 (0.52, 1.87) 0.95 (0.51, 1.78) 0.99 (0.52, 1.89)
At age 70 years 1.11 (0.73, 1.70) 0.92 (0.54, 1.57) 0.94 (0.55, 1.60) 0.94 (0.58, 1.53)











Table 3 Risk of breast cancer according to BMI and mammographic measures, by detection mode and tumor size (Continued)
DA per adjusted 1 SD 2.77 (1.86, 4.14) 2.73 (1.87, 4.00) 2.74 (1.85, 4.05) 2.70 (1.86, 3.92)
PDA per adjusted 1 SD 3.49 (2.19, 5.56) 3.43 (2.18, 5.41)
NDA per adjusted 1 SD 0.58 (0.40, 0.83) 0.58 (0.40, 0.83)
All of the estimates from conditional logistic regression were adjusted for age at mammogram and the variables included into the model. AUC area under the receiver operating characteristic curve, BIC Bayesian
information criterion, BMI body mass index, CI confidence interval, DA dense area, NDA non-dense area, OPERA odds per adjusted standard deviation, PDA percent dense area, SD standard deviation. aLikelihood ratio











Table 4 Risk of interval versus screen-detected cancer according to BMI and mammographic measures
OPERA (95 % CI)
BMI BMI + DA + NDA BMI + PDA BMI + DA DA + NDA PDA DA
All BIC, AUC 527, 0.60 511, 0.68 508, 0.67 518, 0.65 506, 0.67 504, 0.67 514, 0.64
244 SDC/148 IC BMI per 1 SD 0.89 (0.73, 1.09) 0.88 (0.71, 1.08) 0.88 (0.72, 1.08) 0.88 (0.72, 1.08)
DA per adjusted 1 SD 1.46 (1.18, 1.82) 1.52 (1.22, 1.89) 1.46 (1.17, 1.81) 1.51 (1.22, 1.87)
PDA per adjusted 1 SD 1.76 (1.40,2.23) 1.76 (1.39,2.22)
NDA per adjusted 1 SD 0.67 (0.54, 0.83) 0.67 (0.54, 0.84)
Small tumors BIC, AUC 321, 0.65 319, 0.70 314, 0.70 320, 0.67 318, 0.68 313, 0.68 321, 0.65
192 SDC/76 IC BMI per 1 SD 0.67 (0.49, 0.91) 0.72 (0.53, 0.98) 0.72 (0.52, 0.98) 0.68 (0.50, 0.94)
DA per adjusted 1 SD 1.42 (1.05, 1.93) 1.46 (1.08, 1.98) 1.45 (1.08, 1.96) 1.49 (1.10, 2.01)
PDA per adjusted 1 SD 1.73 (1.25, 2.39) 1.79 (1.30, 2.47)
NDA per adjusted 1 SD 0.69 (0.53, 0.91) 0.68 (0.52, 0.89)
Large tumors BIC, AUC 168, 0.57 168, 0.68 166, 0.66 169, 0.63 164, 0.68 161, 0.66 164, 0.63
49 SDC/65 IC BMI per 1 SD 1.10 (0.78,1.54) 0.98 (0.68, 1.43) 1.01 (0.70, 1.45) 1.04 (0.73, 1.47)
DA per adjusted 1 SD 1.44 (0.96, 2.17) 1.48 (1.00, 2.21) 1.44 (0.96, 2.16) 1.49 (1.01, 2.21)
PDA per adjusted 1 SD 1.81 (1.16, 2.83) 1.81 (1.16, 2.82)
NDA per adjusted 1 SD 0.57 (0.35, 0.94) 0.58 (0.35, 0.94)
All of the estimates from unconditional logistic regression were adjusted for age at mammogram and the variables included into the model. AUC area under the receiver operating characteristic curve, BIC Bayesian












nucleotide polymorphisms (SNPs) associated with breast
cancer risk found DA to be a better fit [21]. PDA is
DA divided by total breast area, and is moderately
correlated with BMI (Spearman’s rank correlation = −0.44).
DA, on the other hand, has a weaker correlation with BMI
(Spearman’s rank correlation = −0.28). After adjusting both
measures for age and BMI, PDA was highly associated
with DA, but PDA had undergone two substantial stat-
istical procedures (division and adjustment). Conse-
quently, PDA for age and BMI has more measurement
error than DA for age and BMI.
When restricted to screen-detected cases with small tu-
mors, it is more likely that the tumors were not present on
previous mammography, in which case the risk estimates
would better reflect those for inherent risk of the disease.
This might explain the similarity in the risk model with the
overall cases. Screen-detected large tumors, however, are
plausibly more likely to have been present on previous
mammography and therefore the risk of these tumors
might be influenced by risk of (past) masking in addition
to inherent risk and increased tumor growth rate. This is
perhaps reflected by the fact that the association with BMI
was not age-dependent, as we found from analyses of inter-
val cancers, and of screen-detected versus interval cancers,
which we contend are more about risk of masking.
Risk of interval cancer, on the other hand, represents a
combination of risk of developing the tumor and risk of
masking. This is because, based on the European guide-
line for quality reassurance of screening programs [22],
interval tumors consist of true interval tumors, occult
tumors and false-negative tumors. In our results the age
dependent association between BMI and risk seemed to
have a positive trend but it was not significant, which
could be an indication that risk of interval cancer is not
based solely on risk of developing the tumor. For small
tumors, if we assume that they are mainly true interval
tumors, then the results would be more representative
of inherent risk but the best-fitting risk model in our
study was very different to that for screen-detected small
tumors. This would suggest that there was a high contri-
bution of occult tumors and false-negative tumors
among our small tumors and this might explain the
similarity in results to those for interval tumors overall,
as it also represents a combination of actual risk and risk
of masking. Risk of large tumors, on the other hand,
might be a combination of all three risks; developing the
tumor, masking and rapid growth.
When comparing interval with screen-detected breast
cancers, if we assume that the majority of the screen-
detected tumors were present only on the mammographic
examination at which the tumor was identified and not on
prior mammography, then the predictors are in effect re-
ferring to risk of masking. This is supported by our finding
that the association between risk and BMI did not depend
on age at diagnosis. Our results suggest that the percent-
age, rather than the absolute amount, of “whiteness” on a
mammogram is a stronger risk factor for tumor masking.
Other studies that have investigated PDA (including the
Breast Imaging, Reporting and Data System (BIRADS))
found similar results [23–27]. Results for DA need further
investigation because unlike our study, Boyd et al. [23]
found that DA was associated with increased risk of inter-
val cases compared with screen-detected cases but the as-
sociation disappeared after adjusting for NDA. Studies in
which interval cases detected within one year of the nega-
tive mammogram were defined as those most influenced
by masking, found that greater percent density was a
stronger risk factor for masking [23, 24]. Similar results
were found in our study when we restricted the analysis of
interval cases with small tumors to only those detected
within one year of the negative mammogram. In our
study, when compared with screen-detected cases, interval
cases had less total breast area and more DA and PDA,
and less NDA, which might indicate features of the breast
that are more predictive of masking. When restricted to
small tumors, and therefore possibly reducing the influ-
ence of tumor growth, the best fitting risk model was
similar to that for all tumors, and thus, the risk estimates
for this subgroup of disease might be more appropriate
measures of risk of masking.
Risk of large tumors is hard to interpret due to the pos-
sible influence of tumor growth. MD risk gradients were
significantly greater for large tumors compared with small
tumors, for both detection modes. This observation could
be due to the greater influence of increased tumor growth
rate on large tumors. Two other Australian studies [28, 29]
with larger sample sizes also found MD to be a stronger
risk factor for large vs small screen-detected cancers, but
the difference was not statistically tested. One of the stud-
ies [29], however, found no association between PDA and
risk of screen-detected disease with small tumors. Contrary
to ours, both studies [28, 29] observed greater MD risk
gradients for screen-detected large tumors than interval tu-
mors, but again this was not statistically tested. The differ-
ences, if any, might be due to the different cutoff of 1.5 cm
used to categorize tumors by size, and also to not adjusting
for BMI. Overall, studies estimating the risk gradients for
MD without taking into account the detection mode
and tumor size might produce overestimates of risk
and masking by including large tumors due to the in-
fluence of rapid tumor growth.
One strength of our study is that, as BMI is known to
have differential associations with breast cancer risk [15],
we realistically modelled the BMI association by allowing
it to vary with age at diagnosis. BMI had been calculated
from measured height and weight at cohort entry. To our
knowledge, this is the first study to estimate the differen-
tial risk of developing breast cancer and risk of masking
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by investigating the concurrent associations with all three
measures, DA, NDA and PDA, and by taking into account
the detection mode and tumor size.
A limitation of our study is the sample size, especially
for categories defined by detection and tumor size. We
were not able to retrospectively review mammograms and
identify the proportion of true interval, false-negative, and
occult tumors [27]. If there were fewer occult tumors in
our interval cases, the OPERA estimates corresponding to
MD might be attenuated. We have also assumed the
growth rate to be slower for smaller tumors. In our data,
the time taken for the interval tumors to be diagnosed
after the last scheduled screening was similar for small
and large tumors (mean (SD), 1.08 years (0.61) and
1.00 years (0.52) respectively, P = 0.32). If the tumors oc-
curred at the same time, or if we were able to test this for
true interval cases, this might mean that the larger tumors
were on average growing at a faster rate. Misclassification
of the detection mode of cases might also have occurred if
screen-detected cases were wrongly classified as false-
negative interval cases while true interval cases or occult
tumors were wrongly classified as screen-detected cases.
Other strengths and limitations of the study were dis-
cussed in our previous report [7].
Conclusions
In conclusion, we have gained greater insight into the roles
of MD in breast cancer diagnosis by analyzing cases by
their detection mode and tumor size. After properly taking
into account the role of BMI as a risk factor for disease, we
found that both DA or PDA were predictors of inherent
risk and NDA played no role. For masking, PDA alone was
the best predictor, and BMI was not a risk factor for this
outcome. Consequently, screening strategies could be tai-
lored; e.g., women with greater age-adjusted and BMI-
adjusted DA, who are at higher inherent risk of the disease,
could be recommended prevention strategies, early screen-
ing and/or more frequent screening, taking into account
other measured risk factors such as family history. Women
with greater PDA, irrespective of their BMI, who are at
higher risk of masking, could be recommended for add-
itional screening by ultrasound. Therefore, from the point
of view of using MD measurements to improve screening,
masking and inherent risk need to be thought of as separ-
ate, though interacting, issues.
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